Jonathan I. Epstein
YOU?
Author Swipe
View article: Correction to: Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia
Correction to: Novel, emerging and provisional renal entities: the Genitourinary Pathology Society (GUPS) update on renal neoplasia Open
View article: Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia
Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia Open
View article: Acceptance of emerging renal oncocytic neoplasms: a survey of urologic pathologists
Acceptance of emerging renal oncocytic neoplasms: a survey of urologic pathologists Open
Oncocytic renal neoplasms are a major source of diagnostic challenge in genitourinary pathology; however, they are typically nonaggressive in general, raising the question of whether distinguishing different subtypes, including emerging en…
View article: Detecting suicide risk among U.S. servicemembers and veterans: a deep learning approach using social media data
Detecting suicide risk among U.S. servicemembers and veterans: a deep learning approach using social media data Open
Background Military Servicemembers and Veterans are at elevated risk for suicide, but rarely self-identify to their leaders or clinicians regarding their experience of suicidal thoughts. We developed an algorithm to identify posts containi…
View article: Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis Open
BACKGROUND: Sarcomatoid urothelial cancer of the bladder (SBC) is a rare, but aggressive histological subtype for which novel treatments are needed. OBJECTIVE: We evaluated the clinical activity and safety of neoadjuvant cisplatin plus gem…
View article: JU INSIGHT Biochemical Recurrence in Patients With Grade Group 1 Prostate Cancer With Extraprostatic Extension.
JU INSIGHT Biochemical Recurrence in Patients With Grade Group 1 Prostate Cancer With Extraprostatic Extension. Open
View article: Metastatic Pleomorphic Lobular Carcinoma of the Breast to the Urinary Bladder: A Report of 10 Cases and Assessment of TRPS1 in the Differential Diagnosis With Plasmacytoid Urothelial Carcinoma
Metastatic Pleomorphic Lobular Carcinoma of the Breast to the Urinary Bladder: A Report of 10 Cases and Assessment of TRPS1 in the Differential Diagnosis With Plasmacytoid Urothelial Carcinoma Open
Context.— Metastatic pleomorphic lobular carcinoma (MPLC) to the bladder is rare and has considerable histologic and immunohistochemical overlap with plasmacytoid urothelial carcinoma (PUC). Objective.— To distinguish MPLC from PUC morphol…
View article: Detecting suicide risk among U.S. Servicemembers and Veterans: A deep learning approach using social media data
Detecting suicide risk among U.S. Servicemembers and Veterans: A deep learning approach using social media data Open
Background: Military Servicemembers and Veterans are at elevated risk for suicide, but rarely self-identify to their leaders or clinicians regarding their experience of suicidal thoughts. We developed an algorithm to identify suicidal Serv…
View article: Adenocarcinomas of the Gynecologic Tract Involving the Urinary Bladder: A Series of 16 Cases Potentially Mimicking Urothelial Malignancy
Adenocarcinomas of the Gynecologic Tract Involving the Urinary Bladder: A Series of 16 Cases Potentially Mimicking Urothelial Malignancy Open
Context.— There is limited literature describing gynecologic adenocarcinomas involving the urinary bladder and potential diagnostic pitfalls. Objective.— To describe key features distinguishing metastatic (or extension of) gynecologic aden…
View article: Characterization of <scp>HOXB13</scp> expression patterns in localized and metastatic castration‐resistant prostate cancer
Characterization of <span>HOXB13</span> expression patterns in localized and metastatic castration‐resistant prostate cancer Open
HOXB13 is a key lineage homeobox transcription factor that plays a critical role in the differentiation of the prostate gland. Several studies have suggested that HOXB13 alterations may be involved in prostate cancer development and progre…
View article: Lipoblastoma-Like Tumor and Fibrosarcoma-Like Lipomatous Neoplasm Represent the Same Entity: A Clinicopathologic and Molecular Genetic Study of 23 Cases Occurring in Both Men and Women at Diverse Locations
Lipoblastoma-Like Tumor and Fibrosarcoma-Like Lipomatous Neoplasm Represent the Same Entity: A Clinicopathologic and Molecular Genetic Study of 23 Cases Occurring in Both Men and Women at Diverse Locations Open
View article: Patterns of Immunoreactivity with TTF-1 Antibodies 8G7G3/1 and SPT24 Suggest Distinct Immunoprofiles Between Most Pulmonary and Nonpulmonary Small Cell Carcinomas
Patterns of Immunoreactivity with TTF-1 Antibodies 8G7G3/1 and SPT24 Suggest Distinct Immunoprofiles Between Most Pulmonary and Nonpulmonary Small Cell Carcinomas Open
Introduction. Small cell carcinoma can arise from various sites. Herein, we analyze the ability of 2 thyroid transcription factor-1 (TTF-1) antibodies (SPT24 and 8G7G3/1) to separate pulmonary from nonpulmonary small cell carcinoma. Materi…
View article: Clinicopathologic Classification of Renal Cell Carcinoma in Patients ≤40 Years Old From Peru
Clinicopathologic Classification of Renal Cell Carcinoma in Patients ≤40 Years Old From Peru Open
Introduction There are scant data on renal cell carcinoma (RCC) from relatively younger patients in South America using contemporary classification. Methods Fifty-nine consecutively treated patients with RCC (≤40 years old) were assessed f…
View article: Supplementary Figure 2 from Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
Supplementary Figure 2 from Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma Open
PDF file - 495K, Supplementary Figure S2: (A) Validation of nanoString copy number assessment against copy number calls made using high density SNP array (Affymetrix 6.0) using 4 cases of metastatic castration resistant prostate cancer. Th…
View article: Supp Fig S4 from MSH2 Loss in Primary Prostate Cancer
Supp Fig S4 from MSH2 Loss in Primary Prostate Cancer Open
MSH2/6 immunostains in a formalin fixed and paraffin embedded primary prostate tumor with single copy MSH2 loss by sequencing. Standard tissue section of tumor with apparent single copy somatic gene inactivation of MSH2 (MSH2 c. 1728del), …
View article: Data from MSH2 Loss in Primary Prostate Cancer
Data from MSH2 Loss in Primary Prostate Cancer Open
Purpose: Inactivation of mismatch repair (MMR) genes may predict sensitivity to immunotherapy in metastatic prostate cancers. We studied primary prostate tumors with MMR defects.Experimental Design: A total of 1,133 primary p…
View article: supplemental figure legend and Materials and Methods from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
supplemental figure legend and Materials and Methods from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas Open
supplemental figure legend and Materials and Methods
View article: Supplementary Figure S2 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Supplementary Figure S2 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas Open
Supplementary Figure S2: The ratio of CDKN2A/CCND1 is not as tightly correlated with Rb functional and genetic status in publicly available data from castate resistant prostate cancer (CRPC) metastases in rapid autopsy cohort.
View article: Supp Fig S5 from MSH2 Loss in Primary Prostate Cancer
Supp Fig S5 from MSH2 Loss in Primary Prostate Cancer Open
PD-L1 immunostaining in tumors with MSH2 loss. Standard tissue sections of tumors with MSH2 protein loss shows PD-L1 immunolabeling in lymphocytes predominantly (22966), in lymphocytes and focally in tumor cells (61879) and in lymphocytes …
View article: Supplementary Figure S4 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Supplementary Figure S4 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas Open
Supplementary Figure S4: A high ratio of CDKN2A/CCND1 is associated with shorter interval to development of metastasis among high risk surgically treated men receiving adjuvant androgen deprivation therapy (ADT).
View article: Supplementary Figure S1 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Supplementary Figure S1 from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas Open
Supplementary Figure S1: The ratio of CDKN2A/CCND1 reflects Rb functional and genetic status and distinguishes small cell carcinoma from prostatic adenocarcinoma in publicly available data from patient derived xenografts (PDX).
View article: Data from Pro–Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer
Data from Pro–Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer Open
Purpose: We assessed the association of quantitative clinical and pathologic information, including serum and tissue pro–prostate-specific antigen (proPSA) measurements, with outcomes among men with prostate cancer in an expectant m…
View article: Data from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas
Data from Cyclin D1 Loss Distinguishes Prostatic Small-Cell Carcinoma from Most Prostatic Adenocarcinomas Open
Purpose: Small-cell neuroendocrine differentiation in prostatic carcinoma is an increasingly common resistance mechanism to potent androgen deprivation therapy (ADT), but can be difficult to identify morphologically. We investigated…
View article: Supplementary Tables S1-S5 from A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype
Supplementary Tables S1-S5 from A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype Open
Table S1. Information of antibodies used in MTI Table S2. Multiple logistic regression models for the prediction of aggressiveness and BCR in prostatectomy TMAs: parameters included. Table S3. Multiple logistic regression models for the pr…
View article: Supplementary Table 1 from Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
Supplementary Table 1 from Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma Open
PDF file - 82K, Supplementary Table 1: RB1 status (from high density SNP microarray, Reference 30) and Rb protein status across castrate resistant prostate cancer metastases. n = negative, p = positive, LOH = loss of heterozygosity.
View article: Supp Fig S1 from MSH2 Loss in Primary Prostate Cancer
Supp Fig S1 from MSH2 Loss in Primary Prostate Cancer Open
Validation of MSH2 immunohistochemistry in formalin fixed paraffin embedded prostate cell lines and tumor tissue controls.
View article: Supplementary Methods, Table S1, Figures S1-7 from Development and Clinical Validation of an <i>In Situ</i> Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer
Supplementary Methods, Table S1, Figures S1-7 from Development and Clinical Validation of an <i>In Situ</i> Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer Open
Supplementary Methods, Table S1, Figures S1-7. Methods for quantitative multiplex proteomics imaging (QMPI) Clinical studies: Statistical plan Table S1. Clinical Validation Study. Comparison of Predictive Value of the 8-Biomarker Assay for…
View article: Supp Tables from MSH2 Loss in Primary Prostate Cancer
Supp Tables from MSH2 Loss in Primary Prostate Cancer Open
Supplementary Tables
View article: Supp Fig S1 from MSH2 Loss in Primary Prostate Cancer
Supp Fig S1 from MSH2 Loss in Primary Prostate Cancer Open
Validation of MSH2 immunohistochemistry in formalin fixed paraffin embedded prostate cell lines and tumor tissue controls.
View article: Data from A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype
Data from A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype Open
Background: Early prediction of disease progression in men with very low-risk (VLR) prostate cancer who selected active surveillance (AS) rather than immediate treatment could reduce morbidity associated with overtreatment.Method…